Can a Daily Tablet Prevent Weight Regain After Mounjaro or Wegovy?

Weight-loss injections such as Mounjaro and Wegovy have become a major part of modern weight management. For many people, these treatments can support significant weight loss by reducing appetite, improving fullness, and helping with long-term calorie control. What happens when someone stops taking weight-loss injections?

A new clinical trial has offered an interesting answer. Researchers found that people who had previously used injectable GLP-1 treatments were able to maintain more of their weight loss when they switched to a daily oral GLP-1 pill called orforglipron. The trial, called ATTAIN-MAINTAIN, was published in Nature Medicine and included people who had previously used tirzepatide or semaglutide injections for 72 weeks.

Why Weight Regain Can Happen After Stopping Injections

Weight regain after stopping obesity medication is not simply about willpower. Obesity is widely understood as a chronic and relapsing condition, and the body often responds to weight loss by increasing hunger signals and reducing energy expenditure. This can make long-term weight maintenance difficult after treatment is interrupted.

This is why many clinicians now view weight management as an ongoing process rather than a short-term treatment. Just like blood pressure or cholesterol management, maintaining weight loss may require continued support, lifestyle changes, and in some cases, ongoing medication.

What Did the New Trial Find?

The ATTAIN-MAINTAIN trial followed 376 patients in the US who had previously been treated with either tirzepatide, known as Mounjaro, or semaglutide, known as Wegovy. After completing 72 weeks of injectable treatment, participants were given either a daily orforglipron pill or a placebo for one year.

The results showed that participants who switched to orforglipron maintained much more of their previous weight loss compared with those given a placebo. People who had previously used tirzepatide retained around 75% of their weight loss with orforglipron, compared with around 49% in the placebo group. Those who had previously used semaglutide retained around 79% of their weight loss, compared with around 38% in the placebo group.

Researchers also observed that switching to the tablet helped maintain improvements in markers such as blood pressure, cholesterol, and blood sugar levels.

What Is Orforglipron?

Orforglipron is a once-daily oral GLP-1 receptor agonist. Like injectable GLP-1 treatments, it works by targeting the hormone pathways involved in appetite regulation and fullness. The main difference is that it is taken as a tablet rather than an injection.

This could make long-term treatment easier for people who struggle with injections, travel frequently, or find cold storage and injection routines difficult. However, while the trial results are promising, orforglipron is still not a replacement for personalised medical advice.

Does This Mean Patients Can Stop Mounjaro or Wegovy?

Not necessarily.

The trial suggests that an oral GLP-1 pill may become a useful maintenance option after injectable treatment, but patients should not stop Mounjaro, Wegovy, or any prescribed weight-loss medication without speaking to a healthcare professional.

In the UK, semaglutide and tirzepatide are prescribed under specific clinical criteria, usually alongside diet, physical activity, and ongoing medical review. NHS guidance also highlights that these medicines are part of a wider weight-management plan, not a standalone solution.

What This Could Mean for the Future of Weight Management

The biggest takeaway from this trial is that weight-loss maintenance is becoming a more important part of obesity care. Losing weight is only one stage of treatment. Keeping the weight off safely and sustainably is often the bigger challenge.

If oral GLP-1 treatments become more widely available, they may offer another option for people who have already lost weight with injections but need continued support to maintain their progress.

For now, patients should focus on safe, regulated treatment and regular clinical guidance. Anyone considering weight-loss medication should speak to a qualified prescriber or pharmacist to understand which option is suitable for their health, BMI, medical history, and long-term goals.

Final Thoughts

A daily tablet helping people maintain weight loss after Mounjaro or Wegovy could be an important step forward in obesity treatment. The latest trial data suggests that orforglipron may help reduce weight regain after injectable GLP-1 therapy, but further clinical guidance and regulatory decisions will shape how it is used in practice.

For patients, the message is clear: weight loss treatment should not end with the number on the scale. Long-term maintenance, medical supervision, and healthy lifestyle support remain essential for lasting results.